key: cord-0267654-3do4ajq4
authors: Ma, Chunlong; Wang, Jun
title: Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors
date: 2021-11-05
journal: bioRxiv
DOI: 10.1101/2021.11.04.467342
sha: f56e5fd39b531792099eb03491f347d608bd3871
doc_id: 267654
cord_uid: 3do4ajq4

SARS-CoV-2 encodes two viral cysteine proteases, the main protease (Mpro) and the papain-like protease (PLpro), both of which are validated antiviral drug targets. The PLpro is involved in the cleavage of viral polyproteins as well as immune modulation through removing ubiquitin and interferon-stimulated gene product 15 (ISG15) from host proteins. Therefore, targeting PLpro might be a two-pronged approach. Several compounds including YM155, cryptotanshinone, tanshinone I, dihydrotanshinone I, tanshinone IIA, SJB2-043, 6-thioguanine, and 6-mercaptopurine were recently identified as SARS-CoV-2 PLpro inhibitors through high-throughput screening. In this study, we aim to validate/invalidate the reported PLpro inhibitors using a combination of PLpro target specific assays including enzymatic FRET assay, thermal shift binding assay (TSA), and the cell based FlipGFP assay. Collectively, our results showed that all compounds tested either did not show binding or led to denaturation of the PLpro in the TSA binding assay, which might explain their weak enzymatic inhibition in the FRET assay. In addition, none of the compounds showed cellular inhibition of PLpro as revealed by the FlipGFP assay. Therefore, more efforts are needed to search for specific and potent SARS-CoV-2 PLpro inhibitors.

The COVID-19 pandemic is a timely reminder for the urgent need of antivirals, especially broadspectrum antivirals that could be used as the first line defense against not only current pandemic but also future pandemics. 1 SARS-CoV-2, together with SARS-CoV and MERS-CoV are the three coronaviruses in the β -coronavirus family that caused pandemic/epidemic in human. 2 The SARS-CoV the MERS-CoV had higher mortality rates than SARS-CoV-2. 3 However, SARS-CoV-2 has a much higher transmission rate than SARS-CoV and MERS-CoV, which leads to far greater infection cases and death tolls.

SARS-CoV-2 shares 86% sequence identity with SARS-CoV, which renders the rapid understanding of its viral pathogenicity feasible. SARS-CoV-2 expresses two viral proteases during the viral replication, the main protease (M pro ; nsp5) and the papain-like protease (PL pro ; nsp3). Both are cysteine proteases and have been validated as antiviral drug targets. [4] [5] [6] and M pro cleave the viral polyproteins pp1a and pp1ab at 3 and more than 11 sites, respectively, resulting in individual functional viral proteins for the assembly of viral replication complex.

Compared to PL pro , M pro is a more amenable drug target and has been the central focus of COVID-19 antiviral discovery. Structurally disparate compounds have been reported as M pro inhibitors from either drug repurposing screening or rational design. [7] [8] Although a large number of reported M pro inhibitors were later proven to be promiscuous cysteine modifiers, [9] [10] [11] [12] [13] several M pro inhibitors have been validated as specific inhibitors and have shown in vivo antiviral efficacy in animal model studies. [14] [15] [16] [17] [18] Significantly, two Pfizer M pro inhibitors PF-07304814 and PF-07321332 are advanced to human clinical trials. 17-18 PL pro is second viral cysteine protease that cleaves the viral polypeptide at three different sites during viral replication. In addition, PL pro modulates host immune response by cleaving ubiquitin and ISG15 (interferon-induced gene 15) from host proteins. [19] [20] [21] In contrast to M pro inhibitors, the development of PL pro inhibitors is still at its infancy. 22 The most promising PL pro inhibitors are the naphthalene-based GRL0617 series of compounds ( Figure 1A) . 6, 21, [23] [24] [25] However, their antiviral potency and pharmacokinetic properties need to be further optimized for the in vivo animal model study. PL pro specifically recognize the P1-P4 sequence Gly-Gly-X-Leu that is conserved among the nsp1/2, nsp2/3, and nsp3/4 cleavage sites at the viral polyprotein. 26 The featureless P1 and P2 binding pockets present a grand challenge in developing potent PL pro inhibitors. 26 As the drug-binding site is far away from the catalytic cysteine (> 10Å), majority of the reported PL pro inhibitors are noncovalent inhibitors. 7 Although peptidomimetic covalent PL pro inhibitors have been reported, no antiviral activity was shown. 26 To identify additional novel PL pro inhibitors, several high-throughput screenings have been performed and structurally disparate compounds were found to inhibit PL pro ( Figure 1B ). [27] [28] [29] [30] To evaluate whether any of the identified candidates might worth further pursuing, we are interested in validating/invalidating the reported PL pro inhibitors using a combination of orthogonal assays including the activity-based FRET enzymatic assay, the thermal shift binding (TSA) assay, and the cell-based FlipGFP assay. Collectively, in contrast to the literature reported results, our data showed that the examined non-GRL0617-based PL pro inhibitors ( Figure 1B ) had weak enzymatic inhibition and no cellular PL pro inhibition, therefore they should not be referenced as PL pro inhibitors. 

Through a high-throughput screening of over 6,000 bioactive compounds using a quenched fluorescent substrate RLRGG-AMC, Zhao et al identified four compounds YM155, cryptotanshinone, tanshinone I, and GRL0617 as potent PL pro inhibitors with IC 50 values from 1.39 to 5.63 µM. 29 In plaque reduction assay, YM155, cryptotanshinone, and tanshinone l inhibited SARS-CoV-2 replication in Vero E6 cells with EC 50 values of 0.17, 0.70, and 2.26 µM, respectively. The X-ray crystal structure of SARS-CoV-2 PL pro with YM155 was solved (PDB: 7D7L), revealing three different binding sites in the thumb domain, the zinc-finger motif, and the substrate-binding pocket. In the substrate binding pocket, YM155 induces a conformational change of Y268 on the BL2 loop and forms a π -stacking interaction, which is similar to the binding mode of GRL0617. Binding at the thumb domain likely impedes the interaction between Dose−response curves of the ratio of GFP/mCherry fluorescence with SARS-CoV-2 PL pro inhibitors were plotted at right side column; mCherry signal alone was used to normalize protein expression level or calculate compound cytotoxicity.

In our validation study, the positive control GRL0617 showed similar enzymatic inhibition with an IC 50 of 1.67 µM ( Figure 2A ). However, we found that the enzymatic inhibition potency for YM155, cryptotanshinone, and tanshinone I against PL pro were ~10-fold less active than previously reported and the IC 50 values from our study were 20.16, 52.24, and 18.58 µM, respectively ( Figure 2A and Table 2 ). The discrepancy might be caused by the different substrates used. In

Zhao et al's study, RLRGG-AMC was used, while we used a FRET substrate Dabcyl-FTLRGG/APTKV-Edans which spans both the P and P' sites. Nevertheless, in the thermal shift binding assay, YM155 had no effect on the stability of PL pro , while cryptotanshinone and tanshinone I caused destabilization of the protein ( Figure 2B and Table 2 ). In the cell-based FlipGFP assay, 6 the result for YM155 was not conclusive as it was cytotoxic to the 293T cells ( Figure 2C ). Both cryptotanshinone and tanshinone I were not active (EC 50 > 60 µM) ( Figure   2C ). Overall, our results indicate that cryptotanshinone and tanshinone I were not specific PL pro inhibitors, while YM155 might be a specific PL pro inhibitor. However, the large discrepancy between the enzymatic inhibition (IC 50 = 20.16 µM) and the cellular antiviral activity of YM155 (EC 50 = 0.17 µM) suggest that the other mechanisms might contribute to its potent antiviral activity against SARS-CoV-2. In another study, cryptotanshinone, together with two analogs dihydrotanshinone I and tanshinone IIA were identified as SARS-CoV-2 PL pro inhibitors through a high-throughput screening (HTS). 28 The lack of correlation between the enzymatic inhibition and the cellular antiviral activity might due to cell membrane permeability or off-target effects.

In our validation study, both dihydrotanshinone I and tanshinone IIA were greater than 10-fold less potent in the enzymatic assay with IC 50 values of 33.01 and 15.30 µM, respectively ( Figure   2A and Table 2 ). Dihydrotanshinone I did not bind to PL pro as shown by the results from the TSA assay ( Figure 2B ). Tanshinone IIA led to denaturation of the protein (no melting peak).

Dihydrotanshinone I and tanshinone IIA were not active in the FlipGFP assay (IC 50 > 20 µM) ( Figure 2C ). Overall, it appears that dihydrotanshinone I and tanshinone IIA were not specific SARS-CoV-2 PL pro inhibitors, and the antiviral activity of dihydrotanshinone I might involve other mechanisms. When repeated in our assay, SJB2-043 did not inhibit the SARS-CoV-2 PL pro (IC 50 > 60 µM) ( Figure 2A) . The discrepancy might be caused by different methods used for data fitting. In our assay, SJB2-043 did not achieve more than 50% inhibition at the highest concentration tested, which is 60 µM, therefore we deemed the IC 50 greater than 60 µM. In the TSA binding assay, SJB2-043 led to the destabilization of PL pro (ΔT m = -8.72 µM) ( Figure 2B ). The result from the FlipGFP assay was not conclusive as SJB2-043 was cytotoxic ( Figure 2C ). Overall, SJB2-043 might not be a specific SARS-CoV-2 PL pro inhibitor and only shows partial inhibition.

Swaim et al reported that 6-thioguanine inhibited SARS-CoV-2 replication in Vero E6 cells with an EC 50 of 2.13 µM. 30 Mechanistic studies showed that 6-thioguanine had potent inhibition against PL pro in cells and in vitro using the TAP-nsp123, TAP-nsp23, and Pro-ISG15-HA substrates. Another study from Fu et al showed that 6-thioguanine inhibited SARS-CoV-2 PL pro in the enzymatic assay with an IC 50 of 72 µM. 31 In our study, 6-thioguanine was not active in the FRET-based enzymatic assay (IC 50 > 60 µM) (Figure 2A ). 6-thioguanine also did not show binding in the TSA assay nor inhibition in the FlipGFP assay ( Figures 2B and 2C ). As such, the antiviral activity of 6-thioguanine might involve other mechanisms. 6 mercaptopurine, which is an analog of 6-thioguanine, was similar not active in all three assays ( Figure 2 and Table 2 ).

Therefore, it can be concluded that 6-thioguanine and 6-mercaptopurine were not SARS-CoV-2 PL pro inhibitors.

Drug repurposing is often viewed as a fast-track drug discovery approach since it can potentially bypass the length safety tests before entering clinical trials. 32 However, we should remain cautiously optimistic about this approach. 33 Since the existing bioactive compounds were not specifically designed and optimized for the screening drug target, the identified hits need to be vigorously characterized to validate the target specificity. The SARS-CoV-2 M pro and PL pro are cysteine proteases which are prone to non-specific inhibition by alkylating agents or re-dox cycling compounds. Indeed, our recent studies, together with others, have collectively shown that a number of reported M pro inhibitors including ebselen, carmofur, disulfiram, and shikonin are promiscuous non-specific cysteine protease inhibitors. [9] [10] [11] [12] [13] With our continuous interest in validation/invalidation of literature reported M pro and PL pro inhibitors, in this study we characterized eight PL pro inhibitors using a combination of FRET-based enzymatic assay, TSA binding assay, and the cell-based FlipGFP PL pro assay. It is expected that specific inhibitors will show consistent results from all three assays. Among the compounds tested, cryptotanshinone, tanshinone I, dihydrotanshinone I, and tanshinone IIA were also previously reported as potent SARS-CoV PL pro inhibitors with IC 50 values ranging from 0.8 to 8.8 µM. 34 Interesting, they also inhibited SARS-CoV M pro with IC 50 values ranging from 14.4 to 226.7 µM. Since M pro and PL pro do not share structural and sequence similarities, the dual inhibitory activities of these tanshinones, coupled with the weak PL pro enzymatic inhibition from our study, suggest that they might have a promiscuous mechanism of action.

Similarly shown that all eight compounds had drastically reduced enzymatic inhibition against PL pro compared to reported values (Table 1 ). In addition, all compounds either had no effect or destabilize PL pro as shown by the TSA binding assay (Table 1) . Furthermore, cryptotanshinone, tanshinone I, dihydrotanshinone I, tanshinone IIA, 6-thioguanine, and 6-mercaptopurine were not active in the FlipGFP PL pro assay, suggesting there is a lack of cellular PL pro target engagement. YM155 and SJB2-043 were cytotoxic, therefore it remains unknown whether they can selectively bind to PL pro inside the cell. Overall, our study calls for more stringent validation of the reported SARS-CoV-2 PL pro inhibitors to avoid the failure in the follow up lead optimization and translational development.

Chemicals and peptide substrate. The SARS-CoV-2 PL pro substrate Dabcyl-FTLRGG/APTKV-Edans was synthesized by the solid-phase synthesis and the detailed procedure was described in our previous publication. 6, 10 The testing compounds were ordered from the following sources:

tanshinone I (Sigma T5330), dihydrotanshinone I (Sigma D0947), tanshinone IIA (Sigma The initial velocity of the enzymatic reaction was calculated from the initial 10 min enzymatic reaction. The IC 50 was calculated by plotting the initial velocity against various concentrations of testing compounds by use of a four parameters variable slope dose-response curve in Prism 8

software.

Differential Scanning Fluorimetry (DSF). The thermal shift binding assay (TSA) was carried out using a Thermo Fisher QuantStudio 5 Real-Time PCR system as described previously. 6, 10 Cell-Based FlipGFP-PL pro Assay. Cell-based FlipGFP-PL pro assay was established as previously described. Briefly, 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin antibiotics in a 37 °C incubator with 5% CO 2 . 96-well Greiner plate (catalog no. 655090) was seeded with 293T cells to overnight 70-90% confluency. 50 ng of pcDNA3-flipGFP-PLpro-T2A-mCherry plasmid and 50 ng of pcDNA3.1-SARS2-PL pro were used each well in the presence of transfection reagent TransIT-293 (Mirus) per manufacturer protocol. Three hours after transfection, 1 μ l of testing compound was added to each well at 100-fold dilution. 2 days after transfection images were obatined with a Cytation 5 imaging reader (Biotek) with GFP and mCherry channels. SARS-CoV-2 PL pro protease activity was evaluated by the ratio of GFP signal intensity over the mCherry signal intensity. The compound FlipGFP-PLP assay IC 50 value was calculated by plotting the GFP/mCherry signal to the testing compound concentration with a four-parameter variable slope dose-response function in Prism 8. The mCherry signal alone was utilized to determine the compound cytotoxicity.

Antivirals with common targets against highly pathogenic viruses

Origin and evolution of pathogenic coronaviruses

SARS-CoV-2 (COVID-19) by the numbers

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design

Validation and invalidation of SARS

CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry

Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics

SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model

Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection

Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

Drug Repurposing for the SARS-CoV-2 Papain-Like Protease

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro

The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

Drug repurposing: progress, challenges and recommendations

Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

Thiopurine Analogue Inhibitors of Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease, a Deubiquitinating and deISGylating Enzyme

Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Thiopurine analogs and mycophenolic acid synergistically inhibit the papainlike protease of Middle East respiratory syndrome coronavirus